Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Granger

Showing results (891-900 of 1,023) with videos related to

Pageof 103
Sort By:
Heart Rhythm|July 11, 2025
Atrial fibrillation progression in patients with device-detected subclinical atrial fibrillation: Insights from the ARTESiA trialGiuseppe Boriani, William F McIntyre, Chinthanie Ramasundarahettige, et al.
American Heart Journal|June 2, 2020
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular eventsHarvey D White, Ralph A H Stewart, Anthony J Dalby, et al.
The New England Journal of Medicine|September 3, 2013
Dabigatran versus warfarin in patients with mechanical heart valvesJohn W Eikelboom, Stuart J Connolly, Martina Brueckmann, et al.
American Heart Journal|December 9, 2020
Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) InvestigatorsAnthony P Carnicelli, Hwanhee Hong, Robert P Giugliano, et al.
Journal of the American College of Cardiology|September 4, 2024
Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AFPaul M Haller, Petr Jarolim, Michael G Palazzolo, et al.
Blood|October 17, 2014
Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing proceduresDavid Garcia, John H Alexander, Lars Wallentin, et al.
JACC. Cardiovascular Interventions|June 9, 2022
Clinical Outcomes in Patients With ST-Segment Elevation MI and No Standard Modifiable Cardiovascular Risk FactorsGemma A Figtree, Bjorn Redfors, Rebecca Kozor, et al.
Clinical Trials (London, England)|November 18, 2018
FDA-Catalyst-Using FDA's Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trialNoelle M Cocoros, Sean D Pokorney, Kevin Haynes, et al.
JACC. Advances|June 29, 2026
Clinical Patterns and Appropriateness of Apixaban Dosing in Patients With Atrial FibrillationPishoy Gouda, Josephine Harrington, Kelly Arps, et al.
American Heart Journal|September 29, 2009
Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension (STAT) registryJason N Katz, Joel M Gore, Alpesh Amin, et al.
Pageof 103

Showing results (891-900 of 1,023) with videos related to

Sort By:
Pageof 103
Heart Rhythm|July 11, 2025
Atrial fibrillation progression in patients with device-detected subclinical atrial fibrillation: Insights from the ARTESiA trialGiuseppe Boriani, William F McIntyre, Chinthanie Ramasundarahettige, et al.
American Heart Journal|June 2, 2020
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular eventsHarvey D White, Ralph A H Stewart, Anthony J Dalby, et al.
The New England Journal of Medicine|September 3, 2013
Dabigatran versus warfarin in patients with mechanical heart valvesJohn W Eikelboom, Stuart J Connolly, Martina Brueckmann, et al.
American Heart Journal|December 9, 2020
Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) InvestigatorsAnthony P Carnicelli, Hwanhee Hong, Robert P Giugliano, et al.
Journal of the American College of Cardiology|September 4, 2024
Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AFPaul M Haller, Petr Jarolim, Michael G Palazzolo, et al.
Blood|October 17, 2014
Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing proceduresDavid Garcia, John H Alexander, Lars Wallentin, et al.
JACC. Cardiovascular Interventions|June 9, 2022
Clinical Outcomes in Patients With ST-Segment Elevation MI and No Standard Modifiable Cardiovascular Risk FactorsGemma A Figtree, Bjorn Redfors, Rebecca Kozor, et al.
Clinical Trials (London, England)|November 18, 2018
FDA-Catalyst-Using FDA's Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trialNoelle M Cocoros, Sean D Pokorney, Kevin Haynes, et al.
JACC. Advances|June 29, 2026
Clinical Patterns and Appropriateness of Apixaban Dosing in Patients With Atrial FibrillationPishoy Gouda, Josephine Harrington, Kelly Arps, et al.
American Heart Journal|September 29, 2009
Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension (STAT) registryJason N Katz, Joel M Gore, Alpesh Amin, et al.
Pageof 103